Replies to post #123290 on Biotech Values

[north40000]

Did not Medivir CEO/co. know that JNJ/VRTX collaboration/agreement was extant prior to entering its own with JNJ? Sounds like poor dd to me, and not thinking far enough ahead.

My father was a salesman dealing in a host of school supplies, paper products and the like, calling on drug stores, groceries,dime stores and other variety stores. He presented what he had in his catalog, and the owners would make their choice, often buying more than one product from different mfrs. No problem then with supposed conflicts. The mfrs involved were the likes of Kimberly-Clark, Nekoosa, P&G, etc.

It should make no difference which agreement was in effect first.

[mcbio]

Medivir CEO says JNJ can’t effectively promote two HCV PI’s (Incivek and TMC435):

www.bloomberg.com/news/2011-07-13/j-j-has-to-resolve-hepatitis-c-drug-conflict-medivir-ceo-says.html

Similar to AMLN’s complaint that LLY can’t effectively promote both Tradjenta and Byetta.

Interesting, though I agree with what you posted in #msg-65152026. You know, I've never really taken a close look at Medivir since I thought it might be difficult to invest in given that it's a foreign entity. But, they do have shares that trade on the Pink Sheets (MVRBF.PK). Do you see any downside to investing in Medivir via this route? I just looked at that symbol closer and it shows Medivir having a market cap of only ~$600M. Am I missing something? That seems extremely low to me given their competitive position in the HCV space (ahead of ACHN at not too much higher valuation and have access to the VRUS nukes for the time being and having their own nuke to boot).